189 related articles for article (PubMed ID: 31899613)
1. Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density.
Wang J; Min J; Eghtesadi SA; Kane RS; Chilkoti A
ACS Nano; 2020 Jan; 14(1):372-383. PubMed ID: 31899613
[TBL] [Abstract][Full Text] [Related]
2. The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles.
Wang J; Dzuricky M; Chilkoti A
Nano Lett; 2017 Oct; 17(10):5995-6005. PubMed ID: 28853896
[TBL] [Abstract][Full Text] [Related]
3. Heuristics for the Optimal Presentation of Bioactive Peptides on Polypeptide Micelles.
Wang J; Saha S; Schaal JL; Yousefpour P; Li X; Chilkoti A
Nano Lett; 2019 Nov; 19(11):7977-7987. PubMed ID: 31642326
[TBL] [Abstract][Full Text] [Related]
4. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
5. The effects of ligand valency and density on the targeting ability of multivalent nanoparticles based on negatively charged chitosan nanoparticles.
Cao J; Zhang Y; Wu Y; Wu J; Wang W; Wu Q; Yuan Z
Colloids Surf B Biointerfaces; 2018 Jan; 161():508-518. PubMed ID: 29128837
[TBL] [Abstract][Full Text] [Related]
6. Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells.
Yang Z; Tang W; Luo X; Zhang X; Zhang C; Li H; Gao D; Luo H; Jiang Q; Liu J
J Biomed Nanotechnol; 2015 Aug; 11(8):1401-17. PubMed ID: 26295141
[TBL] [Abstract][Full Text] [Related]
7. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
8. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
Naruphontjirakul P; Viravaidya-Pasuwat K
Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
[No Abstract] [Full Text] [Related]
9. Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.
Soni KS; Lei F; Desale SS; Marky LA; Cohen SM; Bronich TK
J Control Release; 2017 Oct; 264():276-287. PubMed ID: 28870832
[TBL] [Abstract][Full Text] [Related]
10. Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.
Mu Q; Kievit FM; Kant RJ; Lin G; Jeon M; Zhang M
Nanoscale; 2015 Nov; 7(43):18010-4. PubMed ID: 26469772
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
[TBL] [Abstract][Full Text] [Related]
12. Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand.
Vaidyanath A; Hashizume T; Nagaoka T; Takeyasu N; Satoh H; Chen L; Wang J; Kasai T; Kudoh T; Satoh A; Fu L; Seno M
J Cell Mol Med; 2011 Nov; 15(11):2525-38. PubMed ID: 21323863
[TBL] [Abstract][Full Text] [Related]
13. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
14. Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.
Clemons TD; Singh R; Sorolla A; Chaudhari N; Hubbard A; Iyer KS
Langmuir; 2018 Dec; 34(50):15343-15349. PubMed ID: 30441895
[TBL] [Abstract][Full Text] [Related]
15. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
[TBL] [Abstract][Full Text] [Related]
16. Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.
Arpel A; Sawma P; Spenlé C; Fritz J; Meyer L; Garnier N; Velázquez-Quesada I; Hussenet T; Aci-Sèche S; Baumlin N; Genest M; Brasse D; Hubert P; Crémel G; Orend G; Laquerrière P; Bagnard D
Cell Rep; 2014 Sep; 8(6):1714-1721. PubMed ID: 25220456
[TBL] [Abstract][Full Text] [Related]
17. Morphing low-affinity ligands into high-avidity nanoparticles by thermally triggered self-assembly of a genetically encoded polymer.
Simnick AJ; Valencia CA; Liu R; Chilkoti A
ACS Nano; 2010 Apr; 4(4):2217-27. PubMed ID: 20334355
[TBL] [Abstract][Full Text] [Related]
18. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
[TBL] [Abstract][Full Text] [Related]
19. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
20. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
Agus DB; Akita RW; Fox WD; Lewis GD; Higgins B; Pisacane PI; Lofgren JA; Tindell C; Evans DP; Maiese K; Scher HI; Sliwkowski MX
Cancer Cell; 2002 Aug; 2(2):127-37. PubMed ID: 12204533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
